Introduction {#sec1_1}
============

Transient ischemic attack (TIA) is a medical emergency that is associated with a high risk of early ischemic stroke. Carotid artery occlusive lesions \[[@B1],[@B2]\] or intracranial artery occlusive lesions \[[@B3],[@B4],[@B5],[@B6]\] were associated with subsequent stroke after TIA. The Fukuoka Stroke Registry (FSR) examining 693 patients with definite TIA showed that not only carotid arterial stenosis but also intracranial arterial stenosis was significantly associated with stroke in the short and long term for up to 3 years \[[@B7]\]. We also previously reported that large arterial occlusive lesions were significantly associated with recurrent TIA or subsequent ischemic stroke \[[@B8]\].

It is well known that the distribution of atherosclerotic lesions in the cervicocephalic vascular systems varies among different race/ethnic groups. In Caucasians, atherosclerosis develops frequently in the extracranial carotid arteries, whereas intracranial atherosclerosis is a common cause of stroke in Asians \[[@B9],[@B10],[@B11]\]. Thus, it is presumed that TIA attributable to intracranial atherosclerosis is more frequent than that attributable to extracranial carotid atherosclerosis in Japanese.

Several therapeutic strategies, including antiplatelet therapy, statin use, carotid endarterectomy (CEA), and carotid artery stenting (CAS), have been proven to reduce the risk of recurrent stroke in patients with symptomatic extracranial carotid stenosis \[[@B12]\].

In contrast, patients with symptomatic intracranial artery stenosis are still at high risk of stroke recurrence despite medical therapy, including antiplatelet therapy, and risk factor modification. Annual recurrence rates of ischemic stroke were reported to be as high as 15% in the aspirin arm of the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial \[[@B13],[@B14]\] and as high as 12% in the aggressive medical treatment arm of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial \[[@B15],[@B16]\]. The SAMMPRIS trial also demonstrated that angioplasty and stenting in addition to aggressive medical therapy were significantly inferior in terms of safety and efficacy when compared with aggressive medical therapy alone \[[@B15],[@B16]\].

Therefore, we hypothesized that, among TIA patients receiving immediate diagnosis and treatment at a stroke center, those with intracranial artery occlusive lesions would be at higher risk of subsequent ischemic stroke compared with those with extracranial carotid artery occlusive lesions. We aimed to determine the differences in clinical characteristics and the risk of subsequent ischemic stroke between patients with TIA caused by extracranial carotid artery occlusive lesions versus those with TIA caused by intracranial artery occlusive lesions among the patients admitted to our stroke care unit.

Methods {#sec1_2}
=======

Patient Selection {#sec2_1}
-----------------

Between April 2008 and December 2013, 445 patients were admitted to our stroke care unit within 48 h of TIA onset. As a general rule, TIA patients were hospitalized for urgent workup and treatment in our unit if they presented to the hospital within 48 h of TIA onset. An attending physician experienced in stroke medical care made the ultimate diagnosis of TIA and was responsible for management decisions. The diagnosis of TIA was made if focal neurological symptoms ascribable to a vascular etiology lasted \<24 h, irrespective of the presence of ischemic insults on imaging. Patients receiving intravenous thrombolysis or catheter interventions were not included. The carotid and intracranial arteries were assessed by ultrasonography, magnetic resonance angiography (MRA), CT angiography (CTA), and/or digital subtraction angiography (DSA) in all 445 patients.

In this study, a significant occlusive lesion was defined as the presence of ≥50% stenosis or occlusion in the extracranial carotid or intracranial arteries, as detected by any modality. Extracranial carotid arteries included the extracranial internal carotid artery (ICA), and intracranial arteries included the ICA, middle cerebral artery, anterior cerebral artery, vertebral artery, basilar artery, and posterior cerebral artery. In the results of vascular imaging, 138 patients had carotid or intracranial occlusive lesions, including symptomatic and asymptomatic lesions. Of these, 105 patients were considered as having extracranial carotid or intracranial artery occlusive lesions in an appropriate territory to explain their neurological symptoms. Eight patients who were diagnosed as having cervicocephalic artery disease other than atherosclerosis (including dissection and cerebral angiitis) and 12 patients with potential cardioembolic sources, such as atrial fibrillation, were excluded. Finally, a total of 85 patients (63 men, mean age 69.4 ± 11.7 years) were included in this study. We categorized the 85 subjects into two different groups: patients with TIA attributable to extracranial carotid artery occlusive lesions (extracranial group) and those with TIA attributable to intracranial artery occlusive lesions (intracranial group). The hospital\'s ethics committee approved the study protocol.

Patient Characteristics {#sec2_2}
-----------------------

The following patient demographic and clinical characteristics were obtained from review of our stroke database and medical records: sex, age, history of ischemic stroke, ischemic heart disease, hypertension (blood pressure of ≥140/90 mm Hg or use of antihypertensive medications), diabetes mellitus (fasting blood glucose ≥126 mg/dl, positive 75-gram oral glucose tolerance test result, or use of insulin or oral hypoglycemic agents), and dyslipidemia \[serum low-density lipoprotein cholesterol (LDL-Chol) ≥140 mg/dl, high-density lipoprotein cholesterol (HDL-Chol) \<40 mg/dl, triglycerides (TG) ≥150 mg/dl, or use of antidyslipidemic medications\], and current smoking and drinking habits. Multiple TIA was defined as the occurrence of at least two TIAs (the qualifying TIA and one other TIA) within the 90 days prior to the qualifying TIA. We also calculated the ABCD^2^ score for each patient.

Blood Tests {#sec2_3}
-----------

Peripheral venous blood samples were obtained on admission. Tests included measurement of white blood cell count, hemoglobin, hematocrit, platelets, aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, alkaline phosphatase, creatinine, total cholesterol, LDL-Chol, HDL-Chol, TG, glucose, high sensitivity C-reactive protein, and fibrinogen.

Imaging {#sec2_4}
-------

We used the results of the diffusion-weighted imaging (DWI) examination to evaluate whether acute ischemic lesions were present on admission. Extracranial carotid and intracranial arteries were estimated by ultrasonography, MRA, CTA, and/or DSA. The degree of occlusive lesions was classified into three grades: moderate (50-69% stenosis), severe (70-99% stenosis), and occlusion. DSA data were used whenever available. The degree of extracranial carotid artery stenosis was estimated according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method \[[@B17]\], and the degree of intracranial artery stenosis was estimated according to the WASID trial \[[@B13],[@B14]\]. The grade of the degree of intracranial artery stenosis on MRA was identified according to a previously published scoring scheme \[[@B9],[@B18]\].

Clinical Outcomes {#sec2_5}
-----------------

All 85 patients underwent follow-up at 90 days via direct clinical visit or telephone interview. The outcome measure was the occurrence of ischemic stroke within 2 and 90 days of TIA onset. Ischemic stroke was defined by focal neurological deficit lasting \>24 h. Treatments after the qualifying TIA event with oral agents (including aspirin, dual antiplatelet therapy, anticoagulant agents, and statins) and any revascularization procedures (including CEA, CAS, stenting of intracranial artery, and bypass surgery) were recorded.

Statistical Analysis {#sec2_6}
--------------------

All analyses were performed using JMP 10 software (SAS Institute Inc.). Continuous variables were expressed as the mean ± standard deviation (age, blood pressure on admission, and blood test findings) and as the median and interquartile range (IQR; ABCD^2^ score). Categorical data are summarized as percentages. Differences between groups were analyzed using the Student t test and Mann-Whitney U test for continuous values and the Pearson χ^2^ test and Fisher exact test for categorical variables, as appropriate. The risk of ischemic stroke after TIA onset was estimated by Kaplan-Meier event-free survival curves. Statistical test results were considered significant when p \< 0.05.

Results {#sec1_3}
=======

All 85 patients in this study underwent carotid ultrasonography and intracranial MRA. DSA was performed in 42 patients (49.4%). One of 85 patients had both carotid and intracranial artery occlusive lesions. This patient was considered as having extracranial carotid artery occlusive lesions relevant to symptoms because he had severe stenosis in the extracranial carotid artery but moderate stenosis in the intracranial artery. Therefore, 28 patients were considered as having extracranial carotid artery occlusive lesions relevant to symptoms (extracranial group), and 57 patients were considered as having intracranial artery occlusive lesions relevant to symptoms (intracranial group). Intracranial artery occlusive lesions relevant to symptoms were found in middle cerebral artery in 30 patients, ICA in 13 patients, basilar artery in 9 patients, vertebral artery in 4 patients, and anterior cerebral artery in 1 patient.

Table [1](#T1){ref-type="table"} shows a comparison of patient characteristics between the carotid and intracranial groups. Patients in the intracranial group were younger, were less frequently prescribed premorbid antiplatelet agents and statins, had lower levels of fibrinogen, and were less likely to have occlusion when compared with those in the extracranial group. A history of ischemic heart disease tended to be less common, multiple TIA to be more common, and systolic and diastolic blood pressure on admission to be higher in the intracranial group than in the extracranial group. Patients in the intracranial group were less frequently prescribed statins after TIA onset when compared with those in the extracranial group. In the extracranial group, 11 patients underwent revascularization procedures, including seven CEA and four CAS. The timing of these procedures ranged from 13 to 80 days (mean, 33.6 days) after onset of TIA. In the intracranial group, no patient underwent revascularization procedures.

In the extracranial group, no patient had ischemic stroke within 90 days of TIA onset. In the intracranial group, 10 patients had subsequent ischemic stroke within 90 days of TIA onset, and ischemic strokes occurred within 2 days of TIA onset in 8 of these 10 patients. All ten infarcts were found in the territory of arteries with occlusive lesions responsible for the neurological symptoms of qualifying TIA. Cerebral infarctions were detected in the carotid system of 8 patients and in the vertebrobasilar system of 2 patients. Figure [1](#F1){ref-type="fig"} shows Kaplan-Meier ischemic stroke-free survival curves of the extracranial and intracranial groups. Both the 2-day risk (14.2 vs. 0%, p = 0.044) and 90-day risk (17.1 vs. 0%, p = 0.020) of ischemic stroke after TIA onset were significantly higher in the intracranial group than in the extracranial group.

Discussion {#sec1_4}
==========

This study showed that, among 445 patients admitted to our stroke care unit within 48 h of TIA onset, 28 patients (6.3%) had extracranial carotid artery occlusive lesions and 57 patients (12.8%) had intracranial artery occlusive lesions responsible for the neurological symptoms. In a prospective study that enrolled 510 patients with TIA and minor stroke, extracranial carotid artery occlusion or stenosis ≥50% was detected on CTA in 9.4%, and intracranial artery occlusion or stenosis ≥50% was detected on CTA in 20.8% \[[@B4]\]. The FSR showed that 21.8% of patients had carotid stenosis and 22.4% of patients had intracranial stenosis \[[@B7]\]. The incidence of extracranial carotid and intracranial artery occlusive lesions in our study was lower than that in those previous studies. This discrepancy may be partially explained by the fact that we excluded patients diagnosed as having cervicocephalic artery disease other than atherosclerosis and patients with potential cardioembolic sources. We confirmed that intracranial artery occlusive lesions were more common than extracranial carotid artery occlusive lesions in TIA patients with large artery disease.

Patients in the intracranial group were significantly younger, had lower levels of fibrinogen, and were less likely to have occlusion when compared with those in the extracranial group. Several studies have revealed that risk factors are different between extracranial carotid atherosclerosis and intracranial atherosclerosis \[[@B10]\]. To the best of our knowledge, however, no study has investigated the difference in patient characteristics between those with extracranial carotid atherosclerosis and those with intracranial atherosclerosis among TIA patients.

We observed that no patient had a subsequent ischemic stroke within 90 days of TIA onset in the extracranial group, although the extracranial group included only 28 patients. When compared with patients in the intracranial group, patients in the extracranial group were prescribed statins more frequently. In addition, approximately 40% of patients in the extracranial group underwent revascularization procedures within 90 days of TIA onset. Therefore, the revascularization procedures could reduce the 90-day risk of subsequent ischemic stroke in patients with extracranial carotid artery occlusive lesions. However, because the timing of these procedures ranged from 13 to 80 days after TIA onset, we believe that TIA patients with extracranial carotid artery occlusive lesions were at a lower 2-day risk of ischemic stroke when compared with those with intracranial artery occlusive lesions, regardless of the revascularization procedures.

This study showed that in the intracranial group, the 2-day and 90-day risk of subsequent ischemic stroke after TIA was 14.2 and 17.1%, respectively. The WASID trial enrolled patients with TIA or nondisabling stroke within the preceding 3 months and demonstrated a corresponding 50-99% stenosis in a major intracranial artery on angiography \[[@B13],[@B14]\]; in that study, the 7-day and 90-day risk of ischemic stroke in the arterial territory after TIA was 1.4 and 6.9%, respectively. In the SAMMPRIS trial \[[@B15],[@B16]\], in which patients with 70-99% intracranial artery stenosis who had stroke or TIA within the preceding 30 days were randomly assigned to aggressive medical management plus angioplasty and stenting or aggressive medical management alone for stroke prevention, the 30-day rate of stroke or death was 5.8% in the aggressive medical treatment arm. The risk of subsequent ischemic stroke in our patients with intracranial artery occlusive lesions was much higher than that in the WASID and SAMMPRIS trials. The median time from the qualifying event to randomization was 17 days in the WASID trial and 7 days in the SAMMPRIS trial. Therefore, it is conceivable that some patients at higher risk of stroke were excluded from the WASID and SAMMPRIS trials because they were not randomized due to early recurrence. In contrast, subjects in our study were patients who were admitted to our stroke care unit within 48 h of TIA onset, and 80% of recurrent ischemic stroke events occurred within 2 days of TIA onset.

In this study, the diagnosis of TIA was made if focal neurological symptoms ascribable to a vascular etiology lasted \<24 h, irrespective of the presence of ischemic insults on imaging, according to the classical definition of TIA \[[@B19]\]. The advent of brain imaging techniques has led to the understanding that up to one third of patients with symptoms lasting \<24 h actually has an infarction \[[@B20]\]. This resulted in a new tissue-based definition of TIA, that is, 'a transient episode of neurological dysfunction caused by focal brain, spinal cord or retinal ischemia, without acute infarction' \[[@B20]\], which is different from the traditional time-based definition. In present study, DWI lesions were found in 7 (25.0%) of 28 patients in the extracranial group and 20 (35.1%) of 57 patients in the intracranial group. There was no statistically significant difference in DWI positivity between the two groups.

Our study had several limitations. First, the sample size of this study was too small to avoid types 1 and 2 errors. Second, we analyzed only inpatients with TIA using a retrospective design, which might lead to a selection bias. However, most TIA patients were hospitalized for urgent workup and treatment in our unit if they presented to the hospital within 48 h of TIA onset. Therefore, our study patients were essentially consecutive cases. Finally, this study was conducted in a single center. It is necessary to confirm these findings in large multicenter settings to determine if they can be generalized.

In conclusion, among patients with TIA caused by large artery disease, patients with intracranial artery occlusive lesions were more frequent and at a higher risk of early ischemic stroke than those with extracranial carotid artery occlusive lesions. These data highlight the importance of prompt assessment of intracranial artery lesions in patients with TIA.
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Comparison of patients' characteristics between the extracranial and intracranial groups

                                                All patients (n = 85)       Carotid group (n = 28)      Intracranial group (n = 57)   p value
  --------------------------------------------- --------------------------- --------------------------- ----------------------------- ---------
  *Background characteristics*                                                                                                        
  Males                                         63 (74.1)                   23 (82.1)                   40 (70.2)                     0.236
  Age, years                                    69.4±11.7                   73.5±9.3                    67.5±12.3                     0.014
  History of Ischemic stroke                    18 (21.1)                   7 (25.0)                    11 (19.3)                     0.446
   Ischemic heart disease                       15 (17.6)                   8 (28.6)                    7 (12.3)                      0.064
   Hypertension                                 73 (85.9)                   26 (92.9)                   47 (82.5)                     0.196
   Diabetes mellitus                            26 (30.6)                   8 (28.6)                    18 (31.6)                     0.777
   Dyslipidemia                                 51 (60.0)                   20 (71.4)                   31 (54.4)                     0.132
  Multiple TIA                                  27 (31.8)                   5 (17.9)                    22 (37.6)                     0.054
  Current smoking                               19 (22.4)                   5 (17.9)                    14 (24.6)                     0.486
  Current drinking                              35 (41.2)                   11 (39.3)                   24 (42.1)                     0.803
                                                                                                                                      
  *Premorbid treatment*                                                                                                               
  Antiplatelets                                 34 (40.0)                   16 (57.2)                   18 (31.6)                     0.024
  Antihypertensives                             40 (47.1)                   17 (60.7)                   23 (40.4)                     0.077
  Statins                                       24 (28.2)                   12 (42.9)                   12 (21.1)                     0.039
                                                                                                                                      
  *ABCD^2^ score*                                                                                                                     
  SBP on admission, mm Hg                       155.8±26.0                  148.6±29.3                  159.5±23.6                    0.094
  DBP on admission, mm Hg                       84.0±16.7                   78.8±17.7                   86.6±15.8                     0.053
  Clinical features                                                                                                                   
   Unilateral weakness                          66 (77.6)                   25 (89.3)                   41 (71.9)                     0.167
   Speech disturbance without weakness          10 (11.8)                   1 (3.6)                     9 (15.8)                      
  Duration of symptoms                                                                                                                
   \>60 min                                     33 (38.8)                   13 (46.4)                   20 (35.1)                     0.528
   10--59 min                                   39 (45.9)                   12 (42.9)                   27 (47.4)                     
  ABCD^2^ score                                 5 \[[@B4], [@B5], [@B6]\]   5 \[[@B4], [@B5], [@B6]\]   5 \[[@B4], [@B5], [@B6]\]     0.424
                                                                                                                                      
  *Blood test findings*                                                                                                               
  WBC, ×10^3^/µl                                7.5±2.7                     8.1±3.4                     7.2±2.3                       0.222
  Hb, g/dl                                      13.5±1.9                    13.3±2.1                    13.7±1.88                     0.375
  Hct, %                                        40.1±5.6                    39.4±6.0                    40.5±5.4                      0.408
  Platelets, ×10^3^/μl                          222.7±75.5                  232.8±76.9                  217.8±75.0                    0.399
  AST, U/l                                      26.0±18.7                   29.0±29.8                   24.5±9.6                      0.437
  ALT, U/l                                      20.7±17.0                   22.5±25.3                   19.9±11.1                     0.609
  γ-GTP, U/l                                    44.0±68.5                   38.4±26.7                   46.8±81.7                     0.484
  ALP, U/l                                      235.4±66.2                  241.5±62.1                  232.4±68.5                    0.542
  Cre, mg/dl                                    0.93±0.41                   1.01±0.46                   0.89±0.39                     0.239
  T-Chol, mg/dl                                 193.4±39.1                  184.3±34.0                  197.9±40.9                    0.111
  LDL-Chol, mg/dl                               116.4±36.6                  108.9±36.9                  119.8±36.2                    0.213
  HDL-Chol, mg/dl                               48.7±14.5                   47.4±12.0                   49.4±15.6                     0.518
  TG, mg/dl                                     165.2±142.9                 148.8±97.9                  173.3±160.6                   0.387
  Glucose, mg/dl                                137.6±51.7                  147.1±70.7                  132.9±39.1                    0.328
  hs-CRP, mg/dl                                 0.68±2.28                   1.33±3.23                   0.36±1.56                     0.143
  Fibrinogen, mg/dl                             342.4±90.0                  378.9±116.4                 323.9±67.1                    0.026
                                                                                                                                      
  *Imaging findings*                                                                                                                  
  Grade of occlusive lesions                    0.019                                                                                 
   Moderate                                     28 (33.3)                   10 (35.7)                   18 (32.1)                     
   Severe                                       39 (46.4)                   8 (28.6)                    31 (55.4)                     
   Occluded                                     17 (20.3)                   10 (35.7)                   7 (12.5)                      
                                                                                                                                      
  DWI lesions                                   27 (31.8)                   7 (25.0)                    20 (35.1)                     0.348
  *Acute treatment with oral agents*                                                                                                  
  Aspirin                                       78 (91.8)                   26 (92.9)                   52 (91.2)                     0.797
  DAPT                                          29 (34.1)                   9 (32.1)                    20 (35.1)                     0.788
  Anticoagulant agents                          0                           0                           0                             
  Statins                                       51 (60.0)                   22 (78.6)                   29 (50.9)                     0.014
                                                                                                                                      
  Revascularization procedures within 90 days   11 (12.9)                   11 (39.3)                   0                             \<0.001

Values are mean ± SD, n (%) or median \[IQR\]. SBP = Systolic blood pressure; DBP = diastolic blood pressure; WBC = white blood cells; Hb = hemoglobin; Hct = hematocrit; AST = aspartate aminotransferase; ALT = alanine aminotransferase; γ-GTP = γ-glutamyl transpeptidase; ALP = alkaline phosphatase; Cre = creatinine; T-Chol = total cholesterol; hs-CRP = high-sensitivity C-reactive protein; DAPT = dual antiplatelet therapy.
